Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/33039
Type
ArticleCopyright
Open access
Embargo date
2019-11-13
Collections
- INI - Artigos de Periódicos [3516]
- IOC - Artigos de Periódicos [12835]
Metadata
Show full item record
T-CELL-MEDIATED IMMUNE RESPONSES IN PATIENTS WITH CUTANEOUS OR MUCOSAL LEISHMANIASIS: LONG-TERM EVALUATION AFTER THERAPY
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Hospital Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Hospital Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Hospital Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa Hospital Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunomodulação e Protozoologia. Rio de Janeiro, RJ, Brasil.
Abstract
T-cell immune responses in patients with cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML)
were studied during the active disease, at the end of therapy, and 1 to 17 years posttherapy (long-term
follow-up). Lymphocyte proliferative responses, phenotypic characterization of CD4 and CD8 Leishmania reactive T cells, and cytokine production were assayed. Patients with active ML and CL showed higher proportions of CD4 than CD8 T cells. In CL, the healing process was associated with a decrease of CD4 and an increase of CD8 , leading to similar CD4 and CD8 proportions. This pattern was only seen in ML
after long-term therapy. Long-term follow-up of patients with CL showed a positive CD4 /CD8 ratio as
observed during the active disease, although the percentages of these T cell subsets were significantly lower.
Patients with CL did not show significant differences between gamma interferon (IFN-) and interleukin-5
(IL-5) production during the period of study. Patients with active ML presented higher IFN- and IL-5 levels
compared to patients with active CL. IL-4 was only detected during active disease. Patients long term after cure
from ML showed increasing production of IFN-, significant decrease of IL-5, and no IL-4 production. Two
apparently beneficial immunological parameters were detected in tegumentary leishmaniasis: (i) decreasing
proportions of CD4 Leishmania-reactive T cells in the absence of IL-4 production associated with cure of CL
and ML and (ii) decreasing levels of IL-5 long after cure, better detected in patients with ML. The observed
T-cell responses maintained for a long period in healed patients could be relevant for immunoprotection against reinfection and used as a parameter for determining the prognosis of patients and selecting future vaccine preparations.
Share